CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 261 enrolled
Drug / intervention
Magnesium Sulfate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01597557
NCT01597557N/ACompleted
CompareCT.gov

Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial

State University of New York at Buffalo·interventional·Posted May 14, 2012·Updated Oct 22, 2020

In Brief

A clinical study evaluating Magnesium Sulfate and Placebo for Atrial Fibrillation. Completed, enrolled 261 participants across 1 site.

Detailed Summary

The proposed study is designed to evaluate the effect of an intravenous infusion of magnesium sulfate in facilitating successful cardioversion of atrial fibrillation and in decreasing the energy threshold (in J) required for successful cardioversion of atrial fibrillation into sinus rhythm.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 14, 2012
Enrollment StartApr 1, 2012
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.1 years ago

Interventions

Magnesium Sulfatedrug

2 grams intravenous drip over 30 minutes

Placeboother

Normal Saline 50 ml intravenous drip over 30 minutes